JP7808097B2 - 治療タンパク質を生産するための方法 - Google Patents

治療タンパク質を生産するための方法

Info

Publication number
JP7808097B2
JP7808097B2 JP2023518145A JP2023518145A JP7808097B2 JP 7808097 B2 JP7808097 B2 JP 7808097B2 JP 2023518145 A JP2023518145 A JP 2023518145A JP 2023518145 A JP2023518145 A JP 2023518145A JP 7808097 B2 JP7808097 B2 JP 7808097B2
Authority
JP
Japan
Prior art keywords
carboxypeptidase
mab
cpb
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023518145A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542924A5 (https=
JP2023542924A (ja
Inventor
シュー，ジャンリン
ジェン，シュン
エイチ ダウッド，ゼイナブ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2023542924A publication Critical patent/JP2023542924A/ja
Publication of JP2023542924A5 publication Critical patent/JP2023542924A5/ja
Application granted granted Critical
Publication of JP7808097B2 publication Critical patent/JP7808097B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2023518145A 2020-09-22 2021-09-21 治療タンパク質を生産するための方法 Active JP7808097B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063081380P 2020-09-22 2020-09-22
US63/081,380 2020-09-22
US202163225832P 2021-07-26 2021-07-26
US63/225,832 2021-07-26
PCT/US2021/051185 WO2022066595A1 (en) 2020-09-22 2021-09-21 Methods for producing therapeutic proteins

Publications (3)

Publication Number Publication Date
JP2023542924A JP2023542924A (ja) 2023-10-12
JP2023542924A5 JP2023542924A5 (https=) 2024-10-01
JP7808097B2 true JP7808097B2 (ja) 2026-01-28

Family

ID=78135186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518145A Active JP7808097B2 (ja) 2020-09-22 2021-09-21 治療タンパク質を生産するための方法

Country Status (6)

Country Link
US (1) US12486525B2 (https=)
EP (1) EP4217383A1 (https=)
JP (1) JP7808097B2 (https=)
KR (1) KR20230073270A (https=)
CN (1) CN116194570A (https=)
WO (1) WO2022066595A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202548027A (zh) * 2024-01-23 2025-12-16 美商安進公司 用於調節單株抗體電荷變體之方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530891A (ja) 2011-10-27 2014-11-20 ゲンマブ エー／エス ヘテロ二量体タンパク質の作出
JP2016508742A (ja) 2013-03-15 2016-03-24 ロンザ リミテッドＬｏｎｚａ Ｌｉｍｉｔｅｄ 構成的プロモーター
JP2018529341A (ja) 2015-09-22 2018-10-11 ジェネンテック， インコーポレイテッド Ｆｃ含有タンパク質の発現
JP2018184405A (ja) 2011-11-02 2018-11-22 ジェネンテック， インコーポレイテッド オーバーロード／溶出クロマトグラフィー

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
DE68919361T2 (de) 1988-06-21 1995-05-24 Genentech Inc Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
US5126250A (en) 1988-09-28 1992-06-30 Eli Lilly And Company Method for the reduction of heterogeneity of monoclonal antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2193136T3 (es) 1991-08-14 2003-11-01 Genentech Inc Variantes de inmunoglubina para receptores especificos de fc epsilon.
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ES2108566T3 (es) 1993-12-10 1997-12-16 Genentech Inc Procedimientos para diagnosticar alergias y para seleccionar agentes terapeuticos antialergicos.
WO1995019181A1 (en) 1994-01-18 1995-07-20 Genentech, Inc. A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS
US5707622A (en) 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
CA2242414C (en) 1996-01-23 2012-01-03 Genentech, Inc. Anti-cd18 antibodies for use against stroke
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0941344B1 (en) 1996-11-27 2004-05-19 Genentech, Inc. HUMANIZED ANTI-CD11a ANTIBODIES
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
ES2293682T5 (es) 1997-05-15 2011-11-17 Genentech, Inc. Anticuerpo anti-apo2.
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
ES2309012T3 (es) 1999-10-29 2008-12-16 Genentech, Inc. Composiciones del anticuerpo anti-psca y a sus procedimientos contra celulas cancerigenas que expresen psca.
PT2837680T (pt) 2011-07-01 2020-04-17 Amgen Inc Cultura celular de mamífero
US9813410B2 (en) 2014-06-26 2017-11-07 Rakuten, Inc. Information processing apparatus, information processing method, and information processing program
HRP20210830T1 (hr) 2016-10-17 2021-08-20 Enzene Biosciences Ltd. Kontinuirani proces smanjenja heterogenosti terapijskog proteina

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530891A (ja) 2011-10-27 2014-11-20 ゲンマブ エー／エス ヘテロ二量体タンパク質の作出
JP2018184405A (ja) 2011-11-02 2018-11-22 ジェネンテック， インコーポレイテッド オーバーロード／溶出クロマトグラフィー
JP2016508742A (ja) 2013-03-15 2016-03-24 ロンザ リミテッドＬｏｎｚａ Ｌｉｍｉｔｅｄ 構成的プロモーター
JP2018529341A (ja) 2015-09-22 2018-10-11 ジェネンテック， インコーポレイテッド Ｆｃ含有タンパク質の発現

Also Published As

Publication number Publication date
US12486525B2 (en) 2025-12-02
WO2022066595A1 (en) 2022-03-31
US20230357815A1 (en) 2023-11-09
EP4217383A1 (en) 2023-08-02
CN116194570A (zh) 2023-05-30
JP2023542924A (ja) 2023-10-12
KR20230073270A (ko) 2023-05-25

Similar Documents

Publication Publication Date Title
US20250382568A1 (en) Use of perfusion seed cultures to improve biopharmaceutical fedbatch production capacity and product quality
US20170137496A1 (en) Methods to control protein heterogeneity
JP2004532642A (ja) 動物細胞の培養方法と動物細胞でのポリペプチド産生
US20250171732A1 (en) Methods of producing recombinant proteins
US20220315887A1 (en) Methods of improving protein productivity in fed-batch cell cultures
JP7808097B2 (ja) 治療タンパク質を生産するための方法
US20250115666A1 (en) Cell culture methods for producing therapeutic proteins
JP2023538581A (ja) 細胞培養プロセス
WO2026009179A1 (en) Bioreactor process defined by ph and temperature for producing eptinezumab antibodies
EA048403B1 (ru) Способы получения рекомбинантных белков
KR20250022781A (ko) 세포 배양 방법

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240920

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251223

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260116

R150 Certificate of patent or registration of utility model

Ref document number: 7808097

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150